Zelmic is a CRO specialist in topical pharmaceuticals. We were founder in 2002 and have developed several topical drugs and patented technologies for our customers. The company offers services in topical formulation development for small molecules, peptides, and proteins. The analytical capacities are R&D, GMP analysis, validation, and stability studies according to ICH. Zelmic can perform in-vitro release testing (IVRT) and In-vitro permeation testing (IVPT) with skin, nail, and mucous membrane according to new draft EMA guidance. We are now building a GMP facility for clinical manufacture to be completed during 2022.

“Topical is all we do.” CEO, David Sagna